CVS reported fourth-quarter revenue of $93.81 billion, up 12% year-over-year, beating estimates. Adjusted EPS was $2.12 vs an estimated $1.99. The company has reduced its adjusted earnings forecast for 2024 to a minimum of $8.30 per share, a decrease from the earlier projection of at least $8.50 per share, falling short of the expected $8.49 per share. The health services segment saw 12.3% revenue growth to $49.15 billion, beating estimates and driven by specialty pharmacy and acquisitions.